We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
Read MoreHide Full Article
Cardiovascular Systems, Inc. expects fiscal 2018 first-quarter revenues to be affected by the devastating Harvey and Irma hurricanes. Earlier, the company had estimated revenues in the range of $52.6-$53.6 million for the quarter. However, taking effects of the hurricanes into account, the company anticipates a drop in first-quarter 2018 revenues from the previously guided range.
According to Cardiovascular Systems, more than 15% of the company’s revenues are generated from the Houston and Florida.The hurricanes have dented procedure volumes in the greater Houston area and throughout Florida. Moreover, fiscal first quarter revenues are more heavily weighted in September because procedure volumes start to pick up from summer levels. Thus, the company is not confident about meeting the previously guided range for first-quarter revenues.
Though management expects the short-term performance to be affected, the long-term prospects are likely to be untarnished.
In the majority of the last year, Cardiovascular Systems has been trading above the broader industry. Currently, the stock has gained 18.5%, higher than the 10.3% gain of the broader industry. However, the stock lost 7.4% after the announcement on Sep 18, 2017.
Estimate Revision Trend
The estimate revision trend has been unfavorable for the company. For the current quarter, no estimates moved north compared with one movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has fallen from 2 cents to a loss of 7 cents per share over the same period.
Zacks Rank & Key Picks
Cardiovascular Systemscarries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Amedisys, Inc. (AMED - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Amedisys and IDEXX carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 5.7% over the last year.
IDEXX has a long-term expected earnings growth rate of 19.8%. The stock has gained around 45% over the last year.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor’s Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Image: Bigstock
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
Cardiovascular Systems, Inc. expects fiscal 2018 first-quarter revenues to be affected by the devastating Harvey and Irma hurricanes. Earlier, the company had estimated revenues in the range of $52.6-$53.6 million for the quarter. However, taking effects of the hurricanes into account, the company anticipates a drop in first-quarter 2018 revenues from the previously guided range.
According to Cardiovascular Systems, more than 15% of the company’s revenues are generated from the Houston and Florida.The hurricanes have dented procedure volumes in the greater Houston area and throughout Florida. Moreover, fiscal first quarter revenues are more heavily weighted in September because procedure volumes start to pick up from summer levels. Thus, the company is not confident about meeting the previously guided range for first-quarter revenues.
Though management expects the short-term performance to be affected, the long-term prospects are likely to be untarnished.
In the majority of the last year, Cardiovascular Systems has been trading above the broader industry. Currently, the stock has gained 18.5%, higher than the 10.3% gain of the broader industry. However, the stock lost 7.4% after the announcement on Sep 18, 2017.
Estimate Revision Trend
The estimate revision trend has been unfavorable for the company. For the current quarter, no estimates moved north compared with one movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has fallen from 2 cents to a loss of 7 cents per share over the same period.
Zacks Rank & Key Picks
Cardiovascular Systemscarries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Amedisys, Inc. (AMED - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Amedisys and IDEXX carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 5.7% over the last year.
IDEXX has a long-term expected earnings growth rate of 19.8%. The stock has gained around 45% over the last year.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor’s Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>